Epilepsy lifetime prevalence in Iran: a large population- based national survey

Hossein Pakdaman | Ali Amini Harandi | Koroush Gharagozli | Farshid Alaeddini | Akram Esfandani | Seyed Hamidreza Mirbehbahani | Taher Doroudi | Pirhossein Kolivand | Parviz Bahrami | Hadi Kazemi

---

URL :   http://research.shahed.ac.ir/WSR/WebPages/Report/PaperView.aspx?PaperID=158982
Date :  2021/05/03
Publish in :    Scientific Reports
DOI :  https://doi.org/10.1038/s41598-021-89048-z
Link :  http://dx.doi.org/10.1038/s41598-021-89048-z
Keywords :Epilepsy lifetime

Abstract :

---

Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95 CI 15.4–17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3), generalized epilepsy (38) and unknown types of epilepsy (2.7) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15–19 years old 32.7 per 1000 persons (95 CI 29.1–36.8) and it was higher in male (53.8) than female (46.2) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average